Cantor Fitzgerald analyst Joseph France attributes the 6% rally yesterday in shares of Envision Healthcare to news that the company has withdrawn from JPMorgan's healthcare conference scheduled for next month. Envision announced a strategic review in November, and the analyst does not assume that yesterday's development means a transaction is imminent. It is possible that management cannot present because it is not in a position to comment on its outlook or the pending strategic review, France tells investors in a research note after speaking to management. The analyst keeps a Neutral rating on the shares with a $30 price target.